Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Daidzin is a naturally occurring isoflavone glycoside, specifically the 7-O-beta-D-glucoside of daidzein, found in plants such as kudzu (Pueraria lobata). It has been studied primarily for its potential role in the treatment of alcohol dependency due to its antidipsotropic effects. Daidzin acts as a strong, selective, and reversible inhibitor of mitochondrial aldehyde dehydrogenase (ALDH-2), an enzyme involved in ethanol metabolism. By inhibiting ALDH-2, daidzin may suppress ethanol intake by mimicking the effects seen in individuals with inactive ALDH-2 variants who are less prone to alcohol abuse. While it does not inhibit human class I, II, or III alcohol dehydrogenases and does not act as an ethanol-sensitizing agent, further development for alcohol addiction was discontinued. Daidzin is considered experimental and has also been investigated for other pharmacological properties but is mainly recognized for its role in plant metabolism and research on alcohol dependence[1][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on daidzin.